UBS Global Research has downgraded Brenntag to a 'neutral' rating from 'buy,' citing concerns over the company's disappointing profit performance and uncertainties in its restructuring plans. The price target has been reduced to €60 from €80, with potential upside to €105 if profitability improves, but a downside risk could see shares drop to €35 if restructuring fails. Rising selling, general, and administrative expenses have pressured margins, contrasting with peers, and the company faces challenges in executing its planned divisional separation.